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Solid tumors can be difficult to remove completely through standard surgery, depending on their 
location and invasive characteristics. This forces physicians and scientists to explore other therapies 
in order to reduce the risk of relapse by eliminating as many malignant cells as possible. One such 
alternative treatment under development is called adoptive cell therapy, and uses tumor-reactive 
immune cells (T cells) to specifically locate and kill diseased cells. Although promising, the technique 
is in many cases hampered by inefficient tumor homing and poor survival of injected T cells. This 
concern prompted Drs. Sirkka and Matthias Stephan in the Clinical Research Division to investigate 
established surgical protocols in search of "a simple tool" that could increase the clinical efficacy of T 
cell therapy. What they found was biodegradable polymer implants, currently in use for local delivery 
of chemotherapeutic agents to brain cancer patients. The drawback of this technique is 
the passive release of drugs from the polymer, making it hard for the chemotherapeutics to reach 
tumor cells that are more than a few millimeters away from the implant. Consequently, the resulting 
overall survival among treated patients has only been improved to a limited degree. 
Nevertheless, the Stephan Lab saw potential in these polymers as vehicles for T cell delivery and 
generated customized macroporous scaffolds from the US Food and Drug Administration (FDA)-
approved polysaccharide polymerized alginate. To test their effectiveness, the investigators used 
an in vivo mouse breast cancer resection model that mimics tumor recurrence after surgery, and 
embedded the developed T cell-containing scaffolds directly into the cavities from which tumors had 
been incompletely removed. The results were clear: neither intravenous nor intracavitary injection of 
tumor-reactive T cells in solution produced any substantial survival advantages; similarly, 
prestimulation of immune cells with various antibodies and interleukin 15 superagonist improved the 
outcome only modestly. Biopolymer-delivered T cells, on the other hand, effectively reduced the 
relapse rate to zero. 
"Once implanted, T cells actively emigrate deep into the surrounding tumor, where they robustly 
expand (up to 400-fold in our studies), and even infiltrate tumor-draining lymph nodes," explained Dr. 
Matthias Stephan, whose results are hot off the press in the highly ranked scientific journal Nature  
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Biotechnology. The key to the Stephan Lab's success lay in making the scaffolds bioactive, which 
means providing an adhesive coating to support cell egress and stimulatory signals to trigger 
proliferation. This was achieved through integration of collagen-mimetic peptides and porous 
antibody-coated microparticles infused with T cell growth factors, called interleukins. 
The striking effectiveness of the new technique was further studied through bioluminescence 
imaging, showing equally impressive improvements in targeting of tumor sites and proliferation in 
vivo compared with directly injected T cells. Lastly, significant increases in overall survival and time 
to relapse were also demonstrated in a mouse model of late-stage ovarian cancer. 
"We demonstrate for the first time that launching cancer-fighting immune cells from polymeric 
devices can safely and effectively prevent relapse and provide an effective treatment option for 
inoperable tumors," Dr. Stephan said, adding that "implemented in the clinic, biomaterial-supported T 
cell implants could maximize the success of tumor surgery, and spare patients from repetitive 
operations, extended hospital stays, and rounds of radiation or chemotherapy." 
The novel approach shows great potential for resolving two issues that have restricted the clinical 
use of T cell therapy against solid tumors: efficiency and practicality. Compared with adoptive cell 
therapy, which demands time-consuming and expensive procedures for isolation and in 
vitro expansion of the infused T cells, in addition to irradiation and/or immunosuppressing 
pretreatment regimens, the biodegradable scaffolds incorporate all key activation and proliferation 
factors. The released T cells can attack malignant target cells directly, without requiring impairment 
of the patient's own immune system before therapy. 
Encouraged by these advances, the investigators are now continuing their research to include 
delivery of genetically reengineered T cells and other tumor-fighting immune cells, such as natural 
killer cells or invariant natural killer T cells, or even combinations of cell types. "We are also 
developing various injectable polymeric compositions for the minimally invasive implantation of 
active depots of anticancer T cells into poorly accessible or inoperable tumors (e.g., under 
ultrasound guidance)," Dr. Stephan said, adding that their ultimate goal is to implement biomaterial-
supported T cell implants in the clinic, in collaboration with clinical investigators at Fred Hutch. 
Stephan SB, Taber AM, Jileaeva I, Pegues EP, Sentman CL, Stephan MT. 2015. Biopolymer 
implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol 33(1):97-101. 
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Images provided by Dr. Matthias Stephan 
The photographs show biopolymer scaffolds being 
hydrated and loaded with tumor-targeting T cells. The 
schematic diagram demonstrates the action of a T cell-
containing scaffold implanted at a tumor site; green dots 
represent stimulatory microspheres incorporated into the 
polymer framework, which trigger proliferation and 
migration of the T cells (shown in blue) into the surrounding 
tissue as the scaffolding material biodegrades. 
 
 
